Board of Directors
The board of directors of Global Blood Therapeutics is made up of individuals with broad experience and success in the biopharmaceutical industry, as well as the broader political and business community. Our board plays a critical role in providing guidance to the direction of the company.
Mr. Bonney, is a former Partner at Third Rock Ventures, where he focused on the formation, development and strategy for new portfolio companies. Prior to joining Third Rock Ventures, Mr. Bonney served as the chief executive officer and a member of the Board of Directors of Cubist Pharmaceuticals. Prior to Cubist, Mr. Bonney held various positions of increasing responsibility at Biogen, Inc., including vice president, sales and marketing, and at Zeneca Pharmaceuticals, where he held positions in sales, marketing and strategic planning. Mr. Bonney currently serves as chairman of the Board of Directors for Alnylam Pharmaceuticals, Inc., and Bates College. He also serves on the Board of Directors of Celgene Corporation, the Whitehead Institute for Biomedical Research, and the Gulf of Maine Research Institute. He is also a trustee of the Tekla complex of life sciences and healthcare dedicated funds, which include the H&Q Healthcare Investors and H&Q Life Sciences Investors funds. Mr. Bonney earned a B.A. in economics from Bates College.
Willie L. Brown, Jr., has more than 50 years of political, business and non-profit experience. He is a practicing attorney, community leader and well-respected public official who served over 31 years in the California State Assembly, spending more than 14 years as its Speaker. Following his work in the California State Assembly, Mr. Brown served as the 41st mayor of San Francisco, holding the position from January 1996 until January 2004. His tenure as mayor is marked by many well known, large-scale projects including a significant increase in real estate development such as the Mission Bay biotech complex and AT&T baseball stadium, public works, and city beautification.
He currently serves as chairman and chief executive officer of The Willie L. Brown, Jr. Institute on Politics and Public Service, an independent, non-profit organization providing a forum for non-partisan education, debate and discussion of public policy issues.
The Institute is one of the first in the country to focus on local government, dedicated to expanding the resources and expertise available to stakeholders from the political, academic, business and scientific communities.
Mr. Brown earned a degree in political science from San Francisco State University and a J.D. from University of California, Hastings College of the Law. He has received over 17 honorary degrees from prestigious institutions throughout his life.
Ted Love has more than 20 years of broad leadership and management experience in the pharmaceutical industry. Dr. Love most recently served as executive vice president, research and development and technical operations at Onyx Pharmaceuticals, where he played an instrumental role in initiating and completing several of Onyx’s first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion, and previously served as senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held roles of increasing responsibility in medical affairs and product development at Genentech. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan, Herceptin, Xolair, TNKase, Raptiva and Avastin. Dr. Love has served as a consultant in medicine at Massachusetts’s General Hospital in the department of cardiology. Dr. Love currently sits on the board of directors of Amicus Therapeutics and Oncothryeon.
He holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.
Charles Homcy joined Third Rock Ventures in 2010 as a venture partner. Dr. Homcy served as president and chief executive officer of Portola Pharmaceuticals since co-founding the company in 2003 until 2010. Prior to that, Dr. Homcy was the president of research and development at Millennium Pharmaceuticals following Millennium's acquisition of COR Therapeutics in 2002. He joined COR in 1995 as executive vice president of research and development, and he served as a director of the company from 1998 to 2002. Dr. Homcy has been a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital since 1997. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth. He serves as co-chairman of the board of directors of Portola and is a board member of Geron Corporation, Cephalon, Inc., and TOPICA Pharmaceuticals.
Dr. Homcy received his B.A. and M.D. from Johns Hopkins University.
Scott Morrison brings over 35 years of financial experience helping life sciences companies excel from start-up, through initial product launch, to global expansion.
Mr. Morrison has served as Ernst & Young’s U.S. Life Sciences Leader since 2002 (retired December 2015). He has worked on hundreds of public and private financings, including more than 40 IPOs and 100 follow-on offerings and is considered a recognized expert in the M&A arena. Mr. Morrison has a long history of contributions to nonprofit and industry organizations and has previously served on the boards of the Life Sciences Foundation, Bay Area Biosciences Association, the Emerging Companies Section of the Biotechnology Innovation Organization (BIO) and the Biotechnology Institute. Mr. Morrison currently serves on the boards of Audentes Therapeutics, Corvus Pharmaceuticals and Symic Bio.
Mr. Morrison graduated from the University of California, Berkeley and is a Certified Public Accountant (inactive).
Deval L. Patrick is an experienced business and government leader with a record of success in solving complex problems, making strategic investments, managing crises and building teams locally, nationally and internationally. He served as the governor of Massachusetts from 2007 to 2015, during which time he oversaw a more than $36 billion balanced budget and over 44,000 employees. As governor, Mr. Patrick is credited with leading Massachusetts through global economic collapse, weather and water emergencies, and a terrorist attack to top national rankings in job growth, student achievement, health care coverage, economic competitiveness and entrepreneurial activity, among other categories. Prior to his tenure in government, Mr. Patrick served as the chief legal officer and sat on the senior most management teams at the Coca-Cola Company and Texaco, two Fortune 50 companies.
He received a bachelor's degree with concentration in English and American literature from Harvard College and a J.D. from Harvard Law School.
Mark L. Perry brings more than 30 years of experience serving in professional and management positions in the biotechnology industry. He is currently an independent consultant and board member of various companies, following a year as an Entrepreneur-in-Residence at Third Rock Ventures. From 2007 to 2011, Mr. Perry held the position of president and chief executive officer of Aerovance, a biotechnology company spun out of Bayer Corporation. Prior to joining Aerovance, he was the senior business advisor for Gilead Sciences, and was an executive officer of Gilead from 1994 to 2004, serving in a variety of capacities, including general counsel, chief financial officer and executive vice president of operations. He also spent 13 years with Cooley LLP, serving as a partner from 1987 to 1994.
Mr. Perry received his B.A. from the University of California, Berkeley and his J.D. from the University of California, Davis.
Dr. Glenn Pierce retired from Biogen in 2014, where he served in various roles including as chief medical officer for hematology, and as head of global medical affairs, and most recently led the Hematology, Cell and Gene Therapies division. He had overall R&D responsibility for hemophilia and hemoglobinopathies and led the research and clinical development of extended half-life FVIII and FIX Fc fusions, which culminated in multiple regulatory approvals in 2014. He is the co-author of more than 150 scientific papers and has over 15 patents. He is a member of numerous medical and scientific groups including the Hemostasis & Thrombosis Research Society (HTRS), the International Society on Thrombosis and Haemostasis (ISTH) and the American Society of Hematology (ASH). He currently serves on the World Federation of Hemophilia (WFH) and WFHUSA Board of Directors and on the National Hemophilia Foundation (NHF) (U.S.) Medical and Scientific Advisory Council. Previously, he served as president of the Board of the NHF (U.S.). He also served on the U.S. Food and Drug Administration’s (FDA) Blood Products Advisory Committee and the U.S. Department of Health and Human Services’ Committee on Blood Safety and Availability.
Dr. Pierce received an M.D. and a Ph.D. in immunology from Case Western Reserve University in Cleveland and his postgraduate training in pathology and hematology research at Washington University in St. Louis.
Philip Pizzo, M.D., is a leader in academic medicine, championing programs and policies to improve the future of science, education and healthcare in the United States and beyond. He currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. He previously served as Dean of the Stanford School of Medicine from 2001 to 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physician-in-chief of Children’s Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School from 1996-2001. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences.
Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs, has received numerous awards and honors, is a member of the Institute of Medicine and National Academy of Medicine, and serves on several international boards.
Dr. Pizzo received his B.A. from Fordham University and M.D. from the University of Rochester, School of Medicine.